"For decades, families in Europe affected by Rett syndrome have had no medicine specifically approved for the neurobehavioral symptoms of this condition, despite the profound impact they have on almost every aspect of daily life,” said Pedro Rocha, President of Rett Syndrome Europe. “The CHMP’s positive opinion represents hope for thousands of European Union individuals living with this devastating condition, their families and caregivers."

Following the CHMP recommendation, the European Commission will review the opinion and is expected to issue a final decision in the coming months. If DAYBU® is approved, the marketing authorization would apply to all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.

About Rett Syndrome
Rett syndrome is a rare, complex, neurodevelopmental disorder and occurs in approximately one of every 10,000 to 15,000 female births worldwide.1-3 A child with Rett syndrome generally exhi
=*=*=*=*=*=
当前为第3/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页